Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
BR0017030A - Derivados de tiazolilamida - Google Patents
[go: Go Back, main page]

BR0017030A - Derivados de tiazolilamida - Google Patents

Derivados de tiazolilamida

Info

Publication number
BR0017030A
BR0017030A BR0017030-5A BR0017030A BR0017030A BR 0017030 A BR0017030 A BR 0017030A BR 0017030 A BR0017030 A BR 0017030A BR 0017030 A BR0017030 A BR 0017030A
Authority
BR
Brazil
Prior art keywords
thiazolylamide
derivatives
thiazolylamide derivatives
medicaments
novel
Prior art date
Application number
BR0017030-5A
Other languages
English (en)
Other versions
BR0017030B8 (pt
BR0017030B1 (pt
Inventor
Ruediger Fischer
Gerald Kleymann
Ulrich Betz
Judith Baumeister
Wolfgang Bender
Peter Eckenberg
Gabriele Handke
Martin Hendrix
Kerstin Henninger
Axel Jensen
Joerg Keldenich
Udo Schneider
Olaf Weber
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19962532A external-priority patent/DE19962532A1/de
Priority claimed from DE10039265A external-priority patent/DE10039265A1/de
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of BR0017030A publication Critical patent/BR0017030A/pt
Publication of BR0017030B1 publication Critical patent/BR0017030B1/pt
Publication of BR0017030B8 publication Critical patent/BR0017030B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

"DERIVADOS DE TIAZOLILAMIDA". A presente invenção refere-se a novos derivados de tiazolilamida, um processo para a sua preparação bem como seu emprego como medicamentos, especialmente como medicamentos antivirais.
BRPI0017030A 1999-12-23 2000-12-12 derivados de tiazolilamida, processo para sua preparação, composição farmacêutica que os compreende e uso dos mesmos BR0017030B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19962532A DE19962532A1 (de) 1999-12-23 1999-12-23 Thiazolylamid-Derivate
DE10039265A DE10039265A1 (de) 2000-08-11 2000-08-11 Thiazolylamid-Derivate
PCT/EP2000/012564 WO2001047904A1 (de) 1999-12-23 2000-12-12 Thiazolylamid-derivate

Publications (3)

Publication Number Publication Date
BR0017030A true BR0017030A (pt) 2003-01-07
BR0017030B1 BR0017030B1 (pt) 2013-10-01
BR0017030B8 BR0017030B8 (pt) 2021-05-25

Family

ID=26006669

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0017030A BR0017030B8 (pt) 1999-12-23 2000-12-12 derivados de tiazolilamida, processo para sua preparação, composição farmacêutica que os compreende e uso dos mesmos

Country Status (26)

Country Link
US (1) US7105553B2 (pt)
EP (1) EP1244641B1 (pt)
JP (1) JP4726175B2 (pt)
KR (1) KR100768361B1 (pt)
CN (1) CN1235890C (pt)
AR (1) AR029210A1 (pt)
AT (1) ATE293104T1 (pt)
AU (1) AU784286B2 (pt)
BR (1) BR0017030B8 (pt)
CA (1) CA2396720C (pt)
CO (1) CO5261491A1 (pt)
DE (1) DE50010060D1 (pt)
DK (1) DK1244641T3 (pt)
DO (1) DOP2000000109A (pt)
ES (1) ES2240233T3 (pt)
IL (2) IL149897A0 (pt)
MX (1) MXPA02006243A (pt)
MY (1) MY134880A (pt)
NZ (1) NZ519701A (pt)
PE (1) PE20010964A1 (pt)
PL (1) PL208707B1 (pt)
PT (1) PT1244641E (pt)
SV (1) SV2002000249A (pt)
TW (1) TWI256951B (pt)
UY (1) UY26495A1 (pt)
WO (1) WO2001047904A1 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2412720A1 (en) * 2000-06-15 2001-12-20 Bayer Aktiengesellschaft Method for identifying compounds with anti-herpes activity
DE10129714A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Topische Anwendung von Thiazolylamiden
DE10131128A1 (de) * 2001-06-28 2003-01-16 Bayer Ag Sekundäre Sulfonamide
AR037233A1 (es) 2001-09-07 2004-11-03 Euro Celtique Sa Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento
AR036873A1 (es) 2001-09-07 2004-10-13 Euro Celtique Sa Piridinas aril sustituidas a, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento
ATE489965T1 (de) * 2004-09-09 2010-12-15 Novartis Vaccines & Diagnostic Verminderung von potentiellen iatrogenen risiken in verbindung mit influenza impfstoffen
DE102005014248A1 (de) * 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid
CA2618646A1 (en) * 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
WO2007019397A2 (en) * 2005-08-05 2007-02-15 Genelabs Technologies, Inc. 6-membered aryl and heteroaryl derivatives for the treatment of hepatitis c virus
EP1928847A4 (en) * 2005-08-29 2011-08-10 Gerard M Housey THERAMUTEINE MODULATORS
US8030356B2 (en) * 2006-03-17 2011-10-04 Cardioxyl Pharmaceuticals, Inc. N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
JP2010510168A (ja) * 2006-11-22 2010-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 官能化窒化ホウ素ナノチューブ
EP2573085A1 (en) * 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range
EP2573086A1 (en) 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
CA2898798A1 (en) 2013-02-12 2014-08-21 Aicuris Gmbh & Co. Kg Helicase-primase inhibitors for use in a method of treating alzheimer's disease
AU2015287994B2 (en) * 2014-07-07 2020-03-12 Prophylaxis, Llc Viral prophylaxis treatment methods and pre-exposure prophylaxis kits
GEP20207128B (en) * 2016-04-06 2020-07-10 Molecules Gm Innovative Aminothiazole derivatives useful as antiviral agents
AR110250A1 (es) 2016-11-28 2019-03-13 Aicuris Anti Infective Cures Gmbh Formulación tópica que comprende n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida
HUE054703T2 (hu) * 2016-11-28 2021-09-28 Aicuris Gmbh & Co Kg N-[5-(amino-szulfonil)-4-metil-1,3-tiazol-2-il]-N-metil-2-[4-(2-piridinil)fenil]acetamid szabad bázis hemihidrát, annak elõállítási eljárásai és alkalmazásai
TWI753972B (zh) * 2016-11-28 2022-02-01 德商艾庫瑞斯公司 N-[5-(胺基磺醯基)-4-甲基-1,3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)-苯基]-乙醯胺之游離鹼的順丁烯二酸鹽，醫藥調配物、製造方法及其用途
EP3566749A4 (en) * 2017-01-09 2020-09-23 Medshine Discovery Inc. THIAZOLE DERIVATIVE AND USES OF IT
MX2020003369A (es) * 2017-10-05 2020-07-29 Innovative Molecules Gmbh Enantiomeros de tiazoles sustituidos como compuestos antivirales.
US11964969B2 (en) 2018-07-06 2024-04-23 Phaeno Therapeutics Co., Ltd Crystal forms of thiazole compound and application thereof
EP3925595A1 (en) 2020-06-17 2021-12-22 AiCuris GmbH & Co. KG Ophthalmic formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl] acetamide hemihydrate
WO2021191320A1 (en) 2020-03-26 2021-09-30 Aicuris Gmbh & Co. Kg Ophthalmic formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3- thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide hemihydrate
KR20230131177A (ko) 2020-10-29 2023-09-12 이노베이티브 몰리큘스 게엠베하 항바이러스 화합물로서 중수소화된 아미노티아졸 화합물
EP4466255A1 (en) 2022-01-17 2024-11-27 Innovative Molecules GmbH Solid crystalline forms of helicase-primase inhibitors and process of preparation thereof
US12522582B2 (en) 2022-05-20 2026-01-13 Gilead Sciences, Inc. Antiviral indolinyl compounds and uses thereof
JP2025527943A (ja) 2022-08-29 2025-08-25 アセンブリー・バイオサイエンシーズ・インコーポレイテッド 新規な結晶形態
JP2025527942A (ja) 2022-08-29 2025-08-25 アセンブリー・バイオサイエンシーズ・インコーポレイテッド 新規な結晶形態
IL319024A (en) 2022-08-29 2025-04-01 Assembly Biosciences Inc Pharmaceutical preparations for the herpes virus
EP4581029A1 (en) 2022-08-29 2025-07-09 Assembly Biosciences, Inc. Cyclic urea thiazolyl compounds for treatment of hsv
WO2024224304A1 (en) 2023-04-26 2024-10-31 Assembly Biosciences, Inc. Oral pharmaceutical compositions
AU2024334558A1 (en) 2023-08-28 2026-03-19 Assembly Biosciences, Inc. A crystalline form of 2-(3-(2,,5'-difluoro-[1,1'-biphenyl]-4-yl)-2-oxotetrahydropyrimidin-1(2h)-yl)-4-methylthiazole-5-sulfonamide
WO2025046456A1 (en) 2023-08-28 2025-03-06 Assembly Biosciences, Inc. A crystalline form of 2-(3-(2,,5'-difluoro-[1,1'-biphenyl]-4-yl)-2-oxotetrahydropyrimidin-1(2h)-yl)-4-methylthiazole-5-sulfonamide
WO2025111598A1 (en) 2023-11-22 2025-05-30 Assembly Biosciences, Inc. Azetidine compounds for treatment of hsv
WO2025172927A1 (en) 2024-02-16 2025-08-21 Assembly Biosciences, Inc. Pharmaceutical compositions for herpes virus
WO2026015761A1 (en) 2024-07-12 2026-01-15 Assembly Biosciences, Inc. Cyclic urea thiazolyl compound for treatment of viral infections unresponsive to treatment with a first antiviral therapy
WO2026035901A1 (en) 2024-08-07 2026-02-12 Assembly Biosciences, Inc. Tricyclic compounds for treatment of hsv
WO2026035899A1 (en) 2024-08-07 2026-02-12 Assembly Biosciences, Inc. Azetidine compounds for treatment of hsv
US20260042766A1 (en) 2024-08-07 2026-02-12 Assembly Biosciences, Inc. Tricyclic compounds for treatment of hsv
WO2026062572A1 (en) 2024-09-20 2026-03-26 Assembly Biosciences, Inc. Use of a helicase-primase inhibitor in a method of treatment of a herpes virus infection

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3658830A (en) 1970-01-16 1972-04-25 Shell Oil Co 5-(substituted mercapto sulfiny sulfonyl or sulfamoyl)
GB1323045A (en) * 1970-01-16 1973-07-11 Shell Int Research 2-acylaminothiazole derivatives and their use as herbicides
US3847588A (en) 1970-04-20 1974-11-12 Shell Oil Co Thiazoles herbicidal
US3717651A (en) 1970-04-20 1973-02-20 Shell Oil Co Thiazoles
WO1997024343A1 (en) 1995-12-29 1997-07-10 Boehringer Ingelheim Pharmaceuticals, Inc. Phenyl thiazole derivatives with anti herpes virus properties
US5705344A (en) 1996-03-14 1998-01-06 Tularik, Inc. High-throughput screening assay for inhibitors of nucleic acid helicases
GB2311069A (en) 1996-03-14 1997-09-17 Merck & Co Inc Primase isolated from human cytomegalovirus (HCMV)
GB2311068A (en) 1996-03-14 1997-09-17 Merck & Co Inc Helicase isolated from human cytomegalovirus (HCMV)
CA2223032A1 (en) 1997-02-21 1998-08-21 Smithkline Beecham Corporation Use of hsv-1 ul-15 and vp5 in identifying anti-viral agents
DE19802437A1 (de) * 1998-01-23 1999-07-29 Bayer Ag Verwendung von substituierten Sulfonamiden als anitvirale Mittel und neue Stoffe
WO1999042455A1 (en) 1998-02-19 1999-08-26 Tularik Inc. Antiviral agents
CA2320167A1 (en) 1998-03-19 1999-09-23 Steven R. Turner 1,3,4-thiadiazoles useful for the treatment of cmv infections
EP1161423B1 (de) * 1999-03-08 2004-11-10 Bayer HealthCare AG Thiazolylharnstoff-derivate und ihre verwendung als antivirale mittel

Also Published As

Publication number Publication date
NZ519701A (en) 2004-05-28
CA2396720C (en) 2009-09-22
ATE293104T1 (de) 2005-04-15
DE50010060D1 (de) 2005-05-19
PL208707B1 (pl) 2011-05-31
AR029210A1 (es) 2003-06-18
CA2396720A1 (en) 2001-07-05
IL149897A0 (en) 2002-11-10
UY26495A1 (es) 2001-07-31
US20040006076A1 (en) 2004-01-08
BR0017030B8 (pt) 2021-05-25
EP1244641A1 (de) 2002-10-02
TWI256951B (en) 2006-06-21
IL149897A (en) 2008-08-07
DOP2000000109A (es) 2002-08-30
CN1434812A (zh) 2003-08-06
BR0017030B1 (pt) 2013-10-01
PL356484A1 (en) 2004-06-28
AU784286B2 (en) 2006-03-02
DK1244641T3 (da) 2005-07-11
ES2240233T3 (es) 2005-10-16
US7105553B2 (en) 2006-09-12
KR100768361B1 (ko) 2007-10-18
SV2002000249A (es) 2002-06-07
PE20010964A1 (es) 2001-11-10
KR20020067568A (ko) 2002-08-22
CO5261491A1 (es) 2003-03-31
PT1244641E (pt) 2005-08-31
MY134880A (en) 2007-12-31
JP2003519134A (ja) 2003-06-17
CN1235890C (zh) 2006-01-11
JP4726175B2 (ja) 2011-07-20
WO2001047904A1 (de) 2001-07-05
MXPA02006243A (es) 2003-01-28
AU3157401A (en) 2001-07-09
HK1057552A1 (en) 2004-04-08
EP1244641B1 (de) 2005-04-13

Similar Documents

Publication Publication Date Title
BR0017030A (pt) Derivados de tiazolilamida
BR0214870A (pt) 2-tio-3,5-diciano-4-fenil-6-aminopiridinas substituìdas e aplicação das mesmas
MX9503529A (es) Derivados de glicinamida, procedimiento para su preparacion y medicamentos que los contienen.
BR0312513A (pt) Derivados de glicosìdeo de tiofeno, processos para a produção dos mesmos, medicamentos que contêm esses compostos e uso dos mesmos
BR0207726A (pt) Sais farmacêuticos
ECSP034460A (es) Nuevos compuestos heterociclicos, su preparacion y su utilizacion como medicamentos, en especial como antibacterianos
BR0111319A (pt) Composto, processo para preparar um composto, uso de um composto, processo para preparar um sal de um composto, e, composto intermediário
BR9911914B1 (pt) n-arilamidas do ácido sulfonilaminocarboxìlico substituìdas por enxofre, processo para sua preparação, bem como preparações farmacêuticas que compreendem as mesmas.
BR0017043A (pt) Imidazo[1,3,5]triazinonas e sua aplicação
BR0013311A (pt) Derivados substituìdos de 1,5-dihidropirrol-2-ona eficazes como antagonistas de receptores nmda para o tratamento de estados de dor
PT1259498E (pt) Derivados do 8,8a-di-hidroindeno[1,2-d]tiazole substituidos na posicao 8a, processo para a sua preparacao e sua utilizacao como medicamentos, p. ex. como anorecticos
BR0008682A (pt) 3-amino-3-arilpropan-1-ol, processo para sua produção, seu uso e medicamento
BR0108990A (pt) Processo para preparação de derivados de pirimidona com atividade antifungos
BRPI0415203A (pt) pentanóis reestruturados, um processo para sua produção e seu uso como agentes antiinflamatórios
BR0208534A (pt) Processo para preparação de 4,6-diaminopirimido[5,4-d]pirimidinas
BR0013175A (pt) Derivados de vitamina d com sub-estruturas cìclicas na cadeias laterais, processos e produtos intermediários para a sua preparação e a utilização para a preparação de medicamentos
BR0314195A (pt) Derivados de piridina substituìda como agentes antitumorais
BR0013313A (pt) Derivados substituìdos de pirrolidino-2,3,4- triona-3-oxina eficazes como antagonistas de receptores de nmda
BR0016942A (pt) Derivados substituìdos de aminometil-fenil-ciclohexano
BR0113259A (pt) Processo para a preparação de um composto, composto e processo para a preparação de compostos
BR0012622A (pt) Derivados de 3-amino-2-benzil-1-fenil-propano
BR0013084A (pt) Heterociclil-2h-cromenos substituìdos
ES2157419T3 (es) Arilazadioxacicloalquenos substituidos, fungicidas.
BR9810407A (pt) Compostos fluormetoximino
UY26435A1 (es) Compuestos bis-básicos como inhibidores de triptasa, procedimiento para su preparación y su utilización como medicamentos.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: AICURIS GMBH AND CO. KG (DE)

Free format text: TRANSFERIDO DE: BAYER AKTIENGESELLSCHAFT

B25G Requested change of headquarter approved

Owner name: AICURIS GMBH AND CO. KG (DE)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070107873/RJ DE 03/08/2007.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]

Free format text: DE ACORDO COM ART. 34 " II " DA LPI ( LEI 9279, DE 14/05/96 ) , O EXAME FICA SUSPENSO PARA QUE O REQUERENTE APRESENTE DOCUMENTOS NECESSARIOS A REGULARIZACAO DO PROCESSO E EXAME DO PEDIDO.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/10/2013, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/12/2000 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 12/12/2020